You are here:

sofosbuvir/velpatasvir (Epclusa)

Advice

following a full submission:

sofosbuvir-velpatasvir (Epclusa®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.

SMC restriction: in patients with genotype 3 (GT3) chronic HCV infection.

Sofosbuvir-velpatasvir for 12 weeks, compared with sofosbuvir plus ribavirin for 24 weeks, significantly improved sustained virologic suppression in adults with genotype 3 chronic HCV infection.

Drug Details

Drug Name: sofosbuvir/velpatasvir (Epclusa)
SMC Drug ID: 1195/16
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of chronic hepatitis C virus (HCV) infection in adults.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 7 November 2016

Back